'Retatrutida' viraliza nas redes, mas especialistas fazem alerta | #NewsPrimeiraEdição

Summary

The video discusses a new experimental weight-loss injectable called retatrutide, currently being promoted on social media and sold unofficially in Paraguay. Endocrinologist Mateus Galhardo explains that retatrutide is a triple agonist incretin mimetic still undergoing final clinical trials and has not been approved by regulatory authorities like Anvisa. He warns about serious health risks, including gastrointestinal issues, liver damage, and pancreatitis, especially when obtained outside controlled studies. The video emphasizes the dangers of falsified products, social media hype, and the importance of relying on scientific validation and regulatory approval before using such medications.

Takeaways

• 😀 A new injectable pen for weight loss, retatrutide, is being marketed in Paraguay as a quick alternative for weight loss, but it is still in the experimental phase and not yet approved for regular clinical use.
• 😀 The substance is a 'triple agonist' and is an incretin mimetic that affects satiety, glycemic control, and delays gastric emptying.
• 😀 Retatrutide is currently in the final stages of clinical trials and has not yet been approved by regulatory agencies like the FDA, EMA, or ANVISA.
• 😀 The circulating news about retatrutide being launched outside official channels, especially in Paraguay, is concerning as it could lead to counterfeit and illegal distribution of the substance.
• 😀 Retatrutide's official clinical development is ongoing, and any premature launch in unofficial markets raises concerns about safety and authenticity.
• 😀 The popularity of the drug on social media, particularly among influencers, leads to public confusion and a false sense of security about its availability and safety.
• 😀 Social media can create a 'herd mentality,' where people may use the drug without understanding the risks, particularly because the drug is not yet validated by ANVISA in Brazil.
• 😀 Potential side effects of using retatrutide or similar drugs without proper medical guidance could include gastrointestinal issues, liver toxicity, and pancreatitis.
• 😀 Though the ongoing studies for retatrutide show promising results, including significant weight loss, the safety of counterfeit versions is a major concern.
• 😀 The scientific community stresses that medications should be approved by regulatory bodies, not launched based on social media hype or influencer marketing, to avoid health risks.

Q & A

What is retatrutide and why is it being discussed?

Retatrutide is an experimental injectable drug, classified as a triple agonist incretin mimetic. It is being discussed because it is circulating on social media as a quick weight-loss solution, even though it is still under clinical research and not approved for regular medical use.

What are incretins and how do they relate to retatrutide?

Incretins are hormones produced in the intestine that regulate appetite and blood sugar. Retatrutide mimics these hormones, potentially promoting satiety, controlling glucose, and slowing gastric emptying.

Why is retatrutide not yet available for public use?

Retatrutide is still in experimental stages. The lab holding the patent is completing Phase 3 clinical trials, which are needed to ensure the drug's safety and efficacy before regulatory approval by agencies like the FDA, EMA, or Brazil's Anvisa.

What are the risks of obtaining retatrutide from unregulated sources like Paraguay?

Using retatrutide from unofficial sources carries serious risks, including unknown drug composition, falsification, improper storage, and lack of medical monitoring, which can lead to dangerous side effects and legal issues.

What role do social media and influencers play in the spread of unregulated drugs?

Social media often exaggerates the effectiveness of drugs, creating a 'herd effect' where people use the drug without understanding the risks. Influencers can unintentionally mislead the public into thinking unapproved substances are safe.

What are potential side effects of retatrutide?

Potential side effects include gastrointestinal issues like nausea, vomiting, and constipation, as well as serious risks like liver toxicity and pancreatitis, especially if the drug is used without medical supervision.

How does retatrutide compare to existing weight-loss injectables?

Early studies suggest retatrutide may be more effective than current injectables like semaglutide (Monjaro) or tiserpatide, potentially achieving over 24% weight loss in 48 weeks. However, these results are still under clinical investigation.

What is the significance of triple agonist activity in retatrutide?

The triple agonist action, involving GLP-1, GIP, and glucagon pathways, enhances energy expenditure and fat oxidation while minimizing side effects, making the drug potentially more effective for obesity and cardiometabolic conditions.

Why should people prioritize safety over rapid weight loss?

Rapid weight-loss drugs obtained from unregulated sources can pose severe health risks, including hospitalization. Ethical medical research ensures safety and efficacy before a drug is publicly available, so health should always come first.

What is the current status of retatrutide research?

The latest updates indicate that retatrutide has completed Phase 2 trials and is beginning Phase 3 trials, showing promising results for weight loss. Regulatory approval is expected within roughly a year if trials continue successfully.

Why can't doctors officially endorse the use of unapproved retatrutide?

Doctors cannot endorse unapproved drugs because these substances are still under controlled research. Their use outside of trials lacks regulatory approval, verified safety, and quality control, placing patients at significant risk.

What message should the public take from this discussion?

The key message is to avoid unregulated weight-loss drugs and rely on medically approved treatments. Scientific advancements are valuable, but health and safety must come before aesthetic goals or social media trends.